Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gnetin C is a natural stilbenoid and a dimer of resveratrol, primarily extracted from the seeds of the *Gnetum gnemon* (Melinjo) plant. It is currently being investigated for its potent anticancer properties, particularly its ability to overcome therapeutic resistance in castration-resistant prostate cancer (CRPC). The compound acts by disrupting cellular energy metabolism; it downregulates Nicotinamide nucleotide adenylyltransferase 2 (NMNAT2), leading to the depletion of intracellular NAD+ levels. This depletion, combined with the suppression of key mitochondrial proteins and glycolytic enzymes, results in mitochondrial dysfunction and the inhibition of both glycolysis and oxidative phosphorylation. Gnetin C has demonstrated the ability to sensitize darolutamide-resistant cells to treatment, inducing apoptosis through the increased production of reactive oxygen species (ROS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gnetin c.